Tiziana Seeks FDA Orphan Drug Designation for Intranasal Foralumab in MSA
TLSA sits 31% above its 52-week low of $0.762.
Summary
Tiziana Life Sciences has filed for Orphan Drug Designation with the FDA for intranasal foralumab in Multiple System Atrophy, a rare neurodegenerative disease with no approved disease-modifying treatments. The designation, if granted, would provide seven years of market exclusivity and other development incentives.
Key Events · Product Development and Regulatory · TLSA
-
Orphan Drug Designation Request Filed
A request for Orphan Drug Designation has been submitted to the FDA for intranasal foralumab in the treatment of Multiple System Atrophy (MSA).
-
Potential Market Exclusivity
If granted, the designation would provide seven years of market exclusivity upon approval, tax credits for qualified clinical testing, waiver of certain FDA application fees, and eligibility for protocol assistance.
-
FDA Review Timeline
The FDA's Office of Orphan Products Development aims to complete its review of the orphan drug designation request within 90 days of receipt.
-
Ongoing Phase 2a MSA Trial
The designation request follows the company's ongoing Phase 2a open-label trial (NCT06868628) evaluating intranasal foralumab in MSA patients, with PET imaging of microglial activation as a key endpoint.
Analysis · TLSA · Life Sciences
A request for Orphan Drug Designation has been submitted to the FDA for intranasal foralumab in Multiple System Atrophy, a rare and rapidly progressive neurodegenerative disorder with no approved disease-modifying therapies. If granted, the designation would confer seven years of market exclusivity upon approval, tax credits for clinical testing, and waiver of certain FDA application fees. The FDA aims to complete its review within 90 days. This regulatory step builds on the company's ongoing Phase 2a MSA trial and its broader foralumab pipeline, signaling a concrete path toward potential commercial protection in a high-unmet-need indication.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122.4M. The 52-week trading range was $0.76 to $2.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.